TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Self-reported Fruit Intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-reported Vegetable Intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in attendance and truancy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Pathway to care interview
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Costs of formal and informal care giving
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Lactate Dehydrogenase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate in first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inpatient Hospital Length of Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to reach the target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in volumetric bone mineral density at the distal radius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Concordance of self-questionnaire score with DSM-IV criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood and urine levels of varespladib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Average Weekly Pain With Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative Nausea and Vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: hospitalization due to decompensation of HF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain Score on first Mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Percentage Fall in FEV₁
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of ICU-acquired weakness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Functionality of the Critically Ill Patient (Intra-hospital)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FcεRI Levels at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FcεRI Levels at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number and severity of adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant changes in biochemistry, haematology and urinalysis laboratory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant changes in electrocardiogram (ECG) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinically significant changes upon physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic GVHD requiring systemic immunosuppressive treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Re-hospitalization for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Change in Estimated Glomerular Filtration rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Conjunctiva Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fugl-Meyer assessment for UE motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Modified Ashworth scale (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Box and blocks test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Semmes-Weinstein monofilament (SWM) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Motor Activity Log
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Engraftment of peripheral stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital status at discharge
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Kansas City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Open Set Monosyllabic Word Recognition Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrence of uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of mindfulness skills from baseline at 6 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of urge feelings from baseline at 6 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in urge-related behavior engagement from baseline at 6 weeks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of lymph oedema
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Knee adduction moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Knee pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of Positive Pruritus Assessments
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Experiencing at Least a 70% Reduction in Fasting s-BA Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of lopinavir and ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quantification of mitochondrial functions (Oxphos. Leak, RCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of the Lactate threshold in athletes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-progressive survival period
Endpoint domain: Mortality/survival
Primary endpoint: Adherence to smartphone application intervention
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Fluorescence intensity within focal hepatic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft failure Rate
Endpoint domain: Mortality/survival
Primary endpoint: Rate of success of intubation at first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the concentration-time curve (AUC) from the time of dosing extrapolated to time infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eastern Cooperative Oncology Group (ECOG) performance status score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Limb Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS Score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hour supraventricular beat count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: combined ischemic and hemorrhagic endpoint
Endpoint domain: Mortality/survival
Primary endpoint: Change in BOLD response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Patients with Primary Graft Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Right Ventricular Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Meningococcal Serogroup C Serum Bactericidal Assay (rSBA-MenC) Titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Meningococcal Serogroup Y Serum Bactericidal Assay (rSBA-MenY) Titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Hemoglobin A1c (HBA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients reaching target rivastigmine patch size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle Joint Position Sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Joint Position Sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plantar Sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual Task Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perioperative packed red cell transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: modified Rankin Scale scores 0-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of advanced diagnostic tests
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Stimulated Peak Growth Hormone Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percent Change From Baseline in Forearm Vascular Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percent Change From Baseline in Forearm Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Hand writing assessment battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tremor rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Functional dexterity test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale of the European quality of life questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline of the Score at the Hamilton Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: systolic arterial pressure and diastolic arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: heart rate fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dental malocclusion assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Activity Score (CAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Rescue PCA Fentanyl Administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from arrival in CVICU until extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Non-hematologic Toxicity ≥ Grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Specific organ failure in sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficacy as measured by global response assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Patients With Anal Erosion
Endpoint domain: Adverse events/effects
Primary endpoint: Energy requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in M-value (mg/kg lean body mass/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite of Major and Clinically Relevant Minor Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Lower limb kinematics during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Muscle activation patterns during gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Objective Response (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy of SPB block vs thoracic PVB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in visco-elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative overall morbidity rate
Endpoint domain: Adverse events/effects
Primary endpoint: Baseline Resting Cardiac Index (CI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Baseline Resting Stroke Volume Index (SVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pretreatment Peak Exercise CI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pretreatment Peak Exercise SVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of bone or joint infection on implant
Endpoint domain: Adverse events/effects
Primary endpoint: BOLD signal during a combined inhibition-reward-task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional connectivity in the default mode network during resting state (rstfMRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Structural integrity of nerve fibres (DTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum concentration (Cmax) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the time-concentration curve (AUC[0-inf]) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of unsolicited systemic AEs reported in the 30 minutes after injection
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of solicited injection site and systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of unsolicited (spontaneously reported) AEs up to 30 days after injection
Endpoint domain: Adverse events/effects
Primary endpoint: Serotype-specific immunoglobulin type G (IgG) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serotype-specific opsonophagocytic activity (OPA) titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum plasma concentration at steady state (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug concentration in plasma at 12 hours after administration (Cp12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correctly recorded smartwatch ECG lead
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nerve thickness measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in HCV RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with HCV RNA levels below the limit of detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed Cerebral Infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Experiencing Adverse Events (AEs) Defined as Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Grade 2 or Higher Neurologic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Peak dorsiflexion angle during the swing phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maturation of the fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Use of PrEP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lower eyelid Margin Reflex Distance (MRD2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Better Interactions with Oncologists
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change from stone free rate (SFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving C(max) for amikacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AUC (0-24 hr) / MIC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average number of commission errors
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Documented Post-operative Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Circulating Inflammatory Cell Phenotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adherence improvement measured by Tacrolimus trough level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Scale of the Qixu-Xueyu Zheng
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite Surgical Site Infection (SSI) or Other Wound Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Post Operative Pain One Month After Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New DWI Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: OGIS Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total Insulin Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of re-intubation within 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of hypotensive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aerobic Exercise Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hip Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs) by Week 49
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinued From the Study Due to TEAEs by Week 49
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) as Compared to Placebo by Week 49
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Erythrocyte thiamin diphosphate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Scale of therapeutic compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of All Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of menstruation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Endocrine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Volume of menstruation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of Daily Exposure to Secondhand Smoke (SHS) in Indoor Settings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of Exposure to Secondhand Aerosol (SHA) From Electronic Cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rapid Visual Information Processing probability of hit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of clinic appointments until correct diagnosis confirmed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Daily BG Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS-score during movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Plasma peak concentration levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in liver morphology and metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total correction or improvement of facial wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sensitivity of PillCam® Colon 2 Capsule Endoscopy for Polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Specificity of PillCam® Colon 2 Capsule Endoscopy for Polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Attendance at balance-retraining exercise class
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning